D-Pharm considers plugging gap with Thrombotech buy
This article was originally published in Scrip
Executive Summary
D-Pharm has confirmed that it is in talks to acquire fellow Israeli firm Thrombotech. D-Pharm is keen to fill quickly the gap left by the failure of its lead product candidate DP-b99, which was in pivotal Phase III trials as a treatment for acute ischaemic stroke until January this year when an advisory committee concluded that it had little chance of success.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.